Spero Therapeutics, Inc. (SPRO)

NASDAQ: SPRO · Real-Time Price · USD

2.680

+0.040 (1.52%)

Apr 16, 2026, 4:00 PM EDT - Market closed

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Novel Treatments for Multi-Drug Resistant (MDR) Bacterial Infections	66.80M	47.98M	103.78M	53.51M	18.26M
Novel Treatments for Multi-Drug Resistant (MDR) Bacterial Infections Growth	39.24%	-53.77%	93.95%	193.10%	95.67%
Total	66.80M	47.98M	103.78M	53.51M	18.26M
Total Growth	39.24%	-53.77%	93.95%	193.10%	95.67%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
United States	66.80M	47.98M	103.78M	53.51M	18.26M
United States Growth	39.24%	-53.77%	93.95%	193.10%	95.67%
Total	66.80M	47.98M	103.78M	53.51M	18.26M
Total Growth	39.24%	-53.77%	93.95%	193.10%	95.67%

Source: S&P Global Market Intelligence.